Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Wants Global COVID-19 Vaccine Update System, But Says May Not Be Possible

Executive Summary

The agency’s Vaccines and Related Biological Products Advisory Committee will consider simplifying and harmonizing the vaccine composition, as well as formalizing a system for likely annual US updates.

You may also be interested in...



Novavax Readying Multiple COVID-19 Vaccine Candidates To Ensure Fall Availability

CBER’s Marks said US FDA is working with Novavax on manufacturing to allow its protein-based vaccine to be ready for a fall roll-out. After some concerns about international coordination, multiple regulators seem to be settling on a monovalent approach for fall vaccinations.

A Milestone Meeting For US FDA: Vaccine Reviews After COVID

The tandem reviews by a US FDA advisory committee of two RSV vaccine candidates from Pfizer and GSK is a milestone event for the agency. They are the first non-COVID vaccine BLAs to go to committee since the pandemic began – and the debut of the new vaccine office leadership at FDA.

US FDA Investigating Concomitant Flu, COVID Vaccine Link To Stroke Safety Signal

No stroke risk has been identified, but FDA and CDC officials want to investigate whether concomitant administration of influenza and COVID-19 vaccines are related to the issue.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS147622

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel